Insulet (NSDQ:PODD) said today that it's shuffling the executive deck with a slate of hires connected to Hologic (NSDQ:HOLX) and lowered its guidance for the 4th quarter and 2014 overall.
Billerica, Mass.-based Insulet said a delay in shipments of its non-insulin drug delivery products means it now expects to report revenues of $71 million to $73 million, down from prior guidance of $76 million to $81 million. Full-year sales are pegged at $287 to $289 million, down from $292 to $297 million, according to a press release.
Help employers find you! Check out all the jobs and post your resume.
Billerica, Mass.-based Insulet said a delay in shipments of its non-insulin drug delivery products means it now expects to report revenues of $71 million to $73 million, down from prior guidance of $76 million to $81 million. Full-year sales are pegged at $287 to $289 million, down from $292 to $297 million, according to a press release.
Help employers find you! Check out all the jobs and post your resume.
